Merck KGaA generics biz draws suitors

Share this article:
At least five bidders are vying for the generics operation of German pharma firm Merck KGaA, The Wall Street Journal reports. The bids, from other generics firms as well as from private equity, range from $5-$6.5 billion, the newspaper said. Generic drug firms entering bids by this week’s Monday deadline were Teva Pharmaceutical, Mylan Labs, Actavis Group and Ranbaxy Labs. Private-equity firms Bain Capital and Apax Partners made a joint offer, according to the WSJ report. And Indian generics maker Cipla is advising a second offer from a consortium consisting mostly of private-equity companies. Merck KGaA started exploring options for the generics unit, which had 2006 sales of $2.4 billion, last month. Final bids are due by the end of April, a source told the newspaper, with Merck due to compile a short list of suitors by next week. Bear Stearns is handling talks with potential buyers. A successful bid by Ranbaxy would make it the third-biggest biggest generics firm, behind Teva and Novartis’ Sandoz unit.
Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.